End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
114,300 KRW | +0.62% |
|
-0.09% | -8.92% |
06-10 | FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A | CI |
05-20 | Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.92% | 947M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- A006280 Stock
- News GC Biopharma Corp.
- GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates